Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Inclusion Criteria: * Patient having signed the consent form to take part in the study * Patient aged over 18 years, with no upper age limit * Patient with histologically proven cholangiocarcinoma * Patient with cholangiocarcinoma, inoperable or non resectable owing to extension, age or concomitant diseases * Bilirubin level decrease of more than 50% after stent insertion compared to base level * Patient with a WHO Performance Scale ≤ 2 * Patient in whom efficient drainage is performed by means of a plastic biliary stent endoscopically or radiologically * Patient capable of completing the quality of life questionnaires * Women of child-bearing potential must have a negative pregnancy test, and must thereafter prove to be using acceptable contraception (oral contraceptive pill, hormone patches, or IUD) Exclusion Criteria: * Absence of consent to take part in the study * Patient with operable biliary carcinoma * Class ASA IV patients * Patients presenting clinical and laboratory signs of biliary infection * Absence of bilirubin decrease after stent insertion * Patients with extrinsic biliary compression * Patients already having received or currently receiving radiotherapy or chemotherapy for cholangiocarcinoma or needing to be treated during the first month of the follow-up * Known metastatic lesions * Patients having received immediate treatment by insertion of a metal stent * Patients with porphyria or known hypersensitivity to porphyrins (contraindication to WST11) * Patient receiving prohibited treatment at the time of inclusion in the study * Pregnant or breast-feeding women * Non-menopausal women not using effective contraception * Majors under protection as per the French Public Health Code * Persons not registered with or covered by a social security system * Persons in an exclusion period relative to other biomedical study